Presented today at the ESMO Congress 2024* by Maria Vieito, Medical Oncologist at the Vall d’Hebron University Hospital, CORE Phase…
featured news
Among the 518 women enrolled in the international POSITIVE clinical trial with hormone receptor-positive early breast cancer who temporarily interrupted…
Researchers from VHIO are participating in an international study led by IRB Barcelona that identifies five independent factors predicting cancer…
Published open access in Genome Medicine, results of a study led by VHIO’s Experimental Therapeutics Group further support the use…
Based on results from the CAPITello-291 phase III study, co-led by VHIO’s Mafalda Oliveira, Senior Medical Oncologist at Vall d’Hebron…
Results of the phase III LITESPARK-005 clinical trial show that treatment with belzutifan versus everolimus significantly improves progression-free survival in…
Now published in Annals of Oncology (1), updated meta-analysis provides insights into the efficacy of adoptive cell therapy with tumor-infiltrating…
Results of a preclinical, proof-of-concept study led by VHIO’s Stem Cells and Cancer Group demonstrate for the first time the…
More than 150 participants attended the second edition of the PhD Day at the Vall d’Hebron Campus. A day marked…
Announced by the European Medicines Agency (EMA) last month, June 21, the highly selective and potent VEGFR inhibitor fruquintinib has…
